Neuroimmune Dysfunction in Alcohol Use Disorder

Summary

The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.

Conditions

• Alcohol Drinking
• Alcohol-Related Disorders
• Disease
• Inflammation
• Alcoholism
• Cognitive Dysfunction
• Pathologic Processes
• Drinking Behavior
• Substance-Related Disorders
• Chemically-Induced Disorders
• Mental Disorder
• Cognition Disorder
• Neurocognitive Disorders
• Minocycline
• Anti-Bacterial Agents
• Anti-Infective Agents

Interventions

DRUG

Minocycline

200 mg/day

DRUG

Sugar pill

Matched placebo

Sponsors & Collaborators

• National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  collaborator NIH

• University of Maryland, Baltimore

  lead OTHER

Principal Investigators

• Daniel Roche, PhD · University of Maryland, Baltimore

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

25 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-02-03

Primary Completion

2023-09-20

Completion

2023-09-20

FDA Drug

Yes

Countries

• United States

Study Locations